Protara Therapeutics, Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. Our common stock is traded on the Nasdaq Capital Market under the symbol “ TARA ”. Holders of Our common stock As of February 28, 2025, there were 36,767,465 shares of common stock outstanding held by approximately 26 stockholders of record. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, whose shares are held in street name by brokers and other nominees. Dividend Policy We have never declared or paid cash dividends on our common stock, and we do not expect to pay any cash dividends on our common stock in the foreseeable future. Payment of future dividends, if any, on our common stock will be at the discretion of our Board of Directors after taking into account various factors, including our financial condition, operating results, anticipated cash needs, and plans for expansion. Securities Authorized for Issuance under Equity Compensation Plans See Item 12 of Part III of this Annual Report on Form 10-K regarding information about securities authorized for issuance under our equity compensation plans. Recent Sales of Unregistered Securities Common Warrant Exercises On December 12, 2024, 725,000 of the common warrants issued in the Company’s April 2024 private placement were exercised by an investor, at the exercise price of $5.25 per share, resulting in the issuance of 725,000 shares of the Company’s common stock. The securities sold in the April 2024 private placement were issued in reliance upon the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933. The aggregate gross proceeds from the common warrant exercise was approximately $3.8 million. The Company intends to use the proceeds for general corporate and working capital purposes, including funding clinical trials. Item 6. [Reserved.] Not applicable. 70